Skip to main content
. 2022 Oct 28;90(6):511–521. doi: 10.1007/s00280-022-04488-2

Fig. 4.

Fig. 4

Bootstrapped model predictions (n = 1000) of relationship between ipatasertib exposure and safety endpoints in which ipatasertib exposure was retained in the final exposure–safety model (A SAE, B AE leading to discontinuation, C Grade ≥ 2 hyperglycemia). AE adverse event, AUCSS area under the concentration–time curve at steady state, SAE serious adverse event